Clinical characteristics and outcomes of patients hospitalized with heart failure with preserved ejection fraction and low NT-proBNP levels.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
24 Nov 2023
24 Nov 2023
Historique:
medline:
29
11
2023
pubmed:
28
11
2023
entrez:
28
11
2023
Statut:
ppublish
Résumé
The aim of this study was to investigate the clinical characteristics and prognosis of patients hospitalized with heart failure with preserved ejection fraction (HFpEF) and low N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels. Seven hundred ninety consecutive patients hospitalized with HFpEF from 2006 to 2017 were enrolled. Clinical characteristics and outcomes were compared between low NT-proBNP group (<300 ng/L) and elevated NT-proBNP group (≥300 ng/L). 108 HFpEF patients (13.7%) presented with low NT-proBNP levels. Age, body mass index, atrial fibrillation, New York Heart Association functional class, and albumin were independent predictors of low NT-proBNP levels in HFpEF patients. During the median follow-up duration of 1103 days, 11 patients (10.2%) in low NT-proBNP group suffered from primary endpoint event. Elevated NT-proBNP group had a higher risk of all-cause death or heart transplantation than low NT-proBNP group (adjusted HR [95%CI]: 2.36 [1.24,4.49], P = .009). Stratified analyses showed that the association between NT-proBNP (elevated NT-proBNP group vs low NT-proBNP group) and risk of all-cause death or heart transplantation was stronger in non-atrial fibrillation patients than in atrial fibrillation patients (P value for interaction = .025). Furthermore, the associations between NT-proBNP and risk of all-cause death or heart transplantation were stronger in younger and male patients than in older and female patients. However, both subgroups only reached borderline significant (P values for interaction = .062 and .084, respectively). Our findings suggest that low NT-proBNP levels were common in patients hospitalized with HFpEF. Patients with HFpEF and low NT-proBNP levels had a better prognosis than those with elevated NT-proBNP levels, particularly in younger, male, and non-atrial fibrillation patients.
Identifiants
pubmed: 38013260
doi: 10.1097/MD.0000000000036351
pii: 00005792-202311240-00004
pmc: PMC10681576
doi:
Substances chimiques
pro-brain natriuretic peptide (1-76)
0
Natriuretic Peptide, Brain
114471-18-0
Peptide Fragments
0
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e36351Informations de copyright
Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
Groenewegen A, Rutten FH, Mosterd A, et al. Epidemiology of heart failure. Eur J Heart Fail. 2020;22:1342–56.
GBD. 2017 Disease and Injury Incidence and Prevalence Collaborators Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1789–858.
Jones NR, Roalfe AK, Adoki I, et al. Survival of patients with chronic heart failure in the community: a systematic review and meta-analysis. Eur J Heart Fail. 2019;21:1306–25.
McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599–726.
Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2022;145:e895–e1032.
Martinez-Rumayor A, Richards AM, Burnett JC, et al. Biology of the natriuretic peptides. Am J Cardiol. 2008;101:3–8.
Dădârlat-Pop A, Sitar-Tăut A, Zdrenghea D, et al. Profile of obesity and comorbidities in elderly patients with heart failure. Clin Interv Aging. 2020;15:547–56.
Cunningham JW, Vaduganathan M, Claggett BL, et al. Effects of sacubitril/valsartan on N-terminal Pro-B-type natriuretic peptide in heart failure with preserved ejection fraction. JACC Heart Fail. 2020;8:372–81.
Vaishnav J, Chasler JE, Lee YJ, et al. Highest obesity category associated with largest decrease in N-terminal pro-B-type natriuretic peptide in patients hospitalized with heart failure with preserved ejection fraction. J Am Heart Assoc. 2020;9:e015738.
Kristensen SL, Jhund PS, Køber L, et al. Relative importance of history of heart failure hospitalization and N-terminal pro-B-type natriuretic peptide level as predictors of outcomes in patients with heart failure and preserved ejection fraction. JACC Heart Fail. 2015;3:478–86.
Chinese Society of Cardiology of Chinese Medical Association, Editorial Board of Chinese Journal of Cardiology. Chinese guidelines for the diagnosis and treatment of heart failure 2014. Chin J Cardiol. 2014;42:98–122.
Tate S, Griem A, Durbin-Johnson B, et al. Marked elevation of B-type natriuretic peptide in patients with heart failure and preserved ejection fraction. J Biomed Res. 2014;28:255–61.
Meijers WC, Hoekstra T, Jaarsma T, et al. Patients with heart failure with preserved ejection fraction and low levels of natriuretic peptides. Neth Heart J. 2016;24:287–95.
Anjan VY, Loftus TM, Burke MA, et al. Prevalence, clinical phenotype, and outcomes associated with normal B-type natriuretic peptide levels in heart failure with preserved ejection fraction. Am J Cardiol. 2012;110:870–6.
Sakane K, Kanzaki Y, Tsuda K, et al. Disproportionately low BNP levels in patients of acute heart failure with preserved vs reduced ejection fraction. Int J Cardiol. 2021;327:105–10.
Nishikimi T, Nakagawa Y. Potential pitfalls when interpreting plasma BNP levels in heart failure practice. J Cardiol. 2021;78:269–74.
Lopuszynski JB, Downing AJ, Finley CM, et al. Prognosticators of all-cause mortality in patients with heart failure with preserved ejection fraction. Am J Cardiol. 2021;158:66–73.
Lam CSP, Gamble GD, Ling LH, et al. Mortality associated with heart failure with preserved vs reduced ejection fraction in a prospective international multi-ethnic cohort study. Eur Heart J. 2018;39:1770–80.
Kang SH, Park JJ, Choi DJ, et al. Prognostic value of NT-proBNP in heart failure with preserved versus reduced EF. Heart. 2015;101:1881–8.
Sato T, Yamauchi H, Kanno Y, et al. Comparisons of prognostic factors between young and elderly patients with chronic heart failure. Geriatr Gerontol Int. 2015;15:435–42.
Myhre PL, Vaduganathan M, Claggett BL, et al. Association of natriuretic peptides with cardiovascular prognosis in heart failure with preserved ejection fraction: secondary analysis of the TOPCAT randomized clinical trial. JAMA Cardiol. 2018;3:1000–5.
Kotecha D, Lam CS, Van Veldhuisen DJ, et al. Heart failure with preserved ejection fraction and atrial fibrillation: vicious twins. J Am Coll Cardiol. 2016;68:2217–28.
Tromp J, Shen L, Jhund PS, et al. Age-related characteristics and outcomes of patients with heart failure with preserved ejection fraction. J Am Coll Cardiol. 2019;74:601–12.
Nakada Y, Kawakami R, Nakano T, et al. Sex differences in clinical characteristics and long-term outcome in acute decompensated heart failure patients with preserved and reduced ejection fraction. Am J Physiol Heart Circ Physiol. 2016;310:H813–20.
Kim HL, Kim MA, Choi DJ, et al. Gender difference in the prognostic value of N-terminal pro-B type natriuretic peptide in patients with heart failure – a report from the Korean Heart Failure Registry (KorHF). Circ J. 2017;81:1329–36.
Suthahar N, Meems LMG, Ho JE, et al. Sex-related differences in contemporary biomarkers for heart failure: a review. Eur J Heart Fail. 2020;22:775–88.